



**DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors**

Dottikon, Switzerland, July 2, 2010 – At the 5th Annual General Meeting of DOTTIKON ES HOLDING AG for the business year 2009/10 carried out at the "Kultur- und Kongresszentrum TRAF0" in Baden, the shareholders approved all proposals of the Board of Directors. 73 present shareholders represented 1'136'670 voting rights and therefore 94.8% of the total of 1'198'677 registered shares with voting rights.

The Annual Report, financial statements 2009/10 and the consolidated financial statements 2009/10 of DOTTIKON ES HOLDING AG were approved by the Annual General Meeting. Further the proposal of the Board of Directors to carry forward the entire retained earnings to new account and pay no dividend was accepted. Discharge for the business year 2009/10 was granted to the responsible Board of Directors and Management. Members of the Board Heinz Boller and Dr. h.c. Peter Grogg are reelected and Dr. Markus Blocher newly appointed to the Board, all for a term of one year. Statutory auditor for an additional term of one year is KPMG AG, Zurich.

DOTTIKON ES, with its production site in Dottikon (Aargau, Switzerland), is specialized in hazardous chemical reactions and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industry worldwide. The product range of DOTTIKON ES includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates as well as in-house-developed, high-value industrial chemicals.

DOTTIKON ES HOLDING AG is listed at the SIX Swiss Exchange.

Symbol: DESN

Security number: 2073900

ISIN: CH0020739006

For further information please contact

Markus Blocher, Ph.D.  
CEO

Dottikon ES Holding AG  
Tel +41 56 616 82 01  
Fax +41 56 616 89 45  
[investor-relations@dottikon.com](mailto:investor-relations@dottikon.com)